Hospital-Acquired Pneumonia Management Guidelines

Diagnosis and Initial Assessment

Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring ≥48 hours after hospitalization in non-intubated patients, and should be diagnosed based on clinical criteria rather than biomarkers, according to the Infectious Diseases Society of America 1, 3
Respiratory samples should be obtained noninvasively before starting antibiotics to guide targeted therapy and subsequent de-escalation, as recommended by the Infectious Diseases Society of America 1
Distal quantitative samples are preferred in stable patients with suspected ventilator-associated pneumonia (VAP) to reduce unnecessary antibiotic exposure and improve diagnostic accuracy, as suggested by the European Respiratory Society 2

For patients with early-onset HAP and no risk factors for multidrug-resistant (MDR) pathogens, narrow-spectrum antibiotics are recommended by the European Respiratory Society, such as ertapenem, ceftriaxone, cefotaxime, moxifloxacin, or levofloxacin 2
Broad-spectrum empiric therapy is recommended for patients with prior intravenous antibiotic use within 90 days, hospitalization in a unit where >20% of S. aureus isolates are methicillin-resistant, unknown MRSA prevalence in the unit, septic shock or need for ventilatory support due to HAP, recent prolonged hospital stay (>5 days), or previous colonization with MDR pathogens, according to the Infectious Diseases Society of America and the European Respiratory Society 1, 2, 4

For suspected HAP with low risk of MDR pathogens, monotherapy with piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem is recommended by the Infectious Diseases Society of America 4, 5
For suspected HAP with high risk of MDR pathogens, coverage should include S. aureus, Pseudomonas aeruginosa, and other gram-negative bacilli, with recommended agents including vancomycin, linezolid, piperacillin-tazobactam, cefepime, meropenem, and imipenem, as suggested by the Infectious Diseases Society of America and the European Respiratory Society 1, 2, 4

The recommended duration for HAP treatment is 7-14 days, according to the Infectious Diseases Society of America and the European Respiratory Society 1, 3, 6
De-escalate therapy based on culture results and clinical response when available (typically by day 3), as recommended by the European Respiratory Society and the Infectious Diseases Society of America 2, 4

Extended or continuous infusions of β-lactams may be appropriate to optimize pharmacokinetics in patients with HAP, as suggested by the Infectious Diseases Society of America and the European Respiratory Society 4, 5
For multidrug-resistant (MDR) Pseudomonas, combination therapy with polymyxins (colistin) may be necessary, according to the Infectious Diseases Society of America 6
Aminoglycosides should never be used as monotherapy for HAP, even when the isolate appears susceptible, as recommended by the Infectious Diseases Society of America 5